ECI
NBIX icon

EFG Capital International’s Neurocrine Biosciences NBIX Stock Holding History

EFG Capital International’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$296K Buy
+3,140
New +$307K 0.07% 126

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

EFG Capital International's NBIX Position: Q2 2023 in Review

EFG Capital International opened a new position in Neurocrine Biosciences (NBIX) in Q2 2023: 3,140 shares worth $296K. The stake represents 0.07% of the portfolio and ranks #126 among its holdings.

456 funds tracked by Wall St. Rank hold NBIX as of Q2 2023.

  • EFG Capital International held 3,140 shares of Neurocrine Biosciences worth $296K as of Q2 2023.
  • Neurocrine Biosciences was a new EFG Capital International position in Q2 2023.
  • Neurocrine Biosciences made up 0.07% of EFG Capital International's portfolio in Q2 2023, its #126 holding.
  • 456 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2023.

Based on EFG Capital International's 13F filing for Q2 2023, filed 2 Aug 2023.